Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enlivex Therapeutics Ltd ENLV

Healthcare Biotechnology
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages... see more

Recent & Breaking News (NDAQ:ENLV)

BioBlast Pharma Receives Orphan Drug Designation From the European Commission for Cabaletta for the Treatment of Oculopharyngeal Muscular Dystrophy

GlobeNewswire June 25, 2015

BioBlast Announces Positive Preclinical Proof-Of-Concept Results of Its Novel Read-Through Platform in Spinal Muscular Atrophy (SMA)

GlobeNewswire June 22, 2015

BioBlast Pharma to Present Preclinical Proofs of Concept in Spinal Muscular Atrophy and Friedreich's Ataxia at Two Leading Scientific Meetings in June

GlobeNewswire June 18, 2015

BioBlast Announces the Start of a Phase 3 Study for Cabaletta in Oculopharyngeal Muscular Dystrophy (OPMD)

GlobeNewswire June 15, 2015

BioBlast Pharma to Present at Jefferies 2015 Healthcare Conference on June 4th

GlobeNewswire May 27, 2015

BioBlast Pharma Reports First Quarter Financial Results

GlobeNewswire May 19, 2015

BioBlast Pharma Announces Granting of Fast Track Designation by the FDA for Cabaletta in Oculopharyngeal Muscular Dystrophy (OPMD)

GlobeNewswire April 9, 2015

BioBlast Pharma Announces Positive in vivo Preclinical Proof-of-Concept Results of Its Cabaletta Platform in Spinocerebellar Ataxia Type 3 (SCA3)

GlobeNewswire March 30, 2015

BioBlast Pharma Announces Positive Preclinical Proof-of-Concept Results of Its Novel Mitochondrial Protein Replacement Platform in Friedreich's Ataxia

GlobeNewswire March 26, 2015

BioBlast Receives IND Clearance to Commence Clinical Trial for Cabaletta for the Treatment of OPMD

GlobeNewswire March 12, 2015

BioBlast Pharma to Present at the 27th Annual ROTH Investor Conference

GlobeNewswire March 5, 2015

BioBlast Receives Notice of Allowance From USPTO Covering Cabaletta for the Treatment of OPMD

GlobeNewswire February 24, 2015

BioBlast Pharma Reports Fourth Quarter Financial Results

GlobeNewswire February 17, 2015

Bio Blast Pharma to Release Fourth Quarter and Fiscal Year 2014 Results on Tuesday, February 17

GlobeNewswire February 10, 2015

Bio Blast Announces Key Leadership Changes

GlobeNewswire February 2, 2015

Bio Blast Provides Update on Clinical Trial of Cabaletta(TM) for Occulopharyngeal Muscular Dystrophy (OPMD)

GlobeNewswire January 8, 2015

BioBlast Receives Notice of Patent Issuance From USPTO for Its Novel Fusion Protein-Based Platform for the Treatment of Friedrich's Ataxia

GlobeNewswire December 17, 2014

Bio Blast Pharma to Present Corporate Overview at the Oppenheimer & Co. 25th Annual Healthcare Conference

GlobeNewswire December 2, 2014

Bio Blast Pharma Reports Third Quarter Financial Results

GlobeNewswire November 21, 2014

Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA for Cabaletta for the Treatment of Spinocerebellar Ataxia Type 3

GlobeNewswire November 19, 2014